Radioguided Surgery of Thyroid Carcinoma Recurrences

  • Christina Bluemel
  • Ken Herrmann
  • Gerhard Wolf
  • Giorgo Castagnola
  • Carlo Bellotti
Chapter
First Online:

Abstract

Thyroid cancer is the most common endocrine malignancy. The most frequent subtypes are differentiated thyroid cancer arising from the thyroid follicular epithelial cells and medullary thyroid cancer. The overall prognosis of patients with thyroid cancer is good, but more than one-third of patients experience recurrent disease. Patients with local recurrence in the thyroid bed or cervical lymph node metastases are usually treated with surgery, which may be complicated by the distorted anatomy due to total thyroidectomy and lymph node dissection for primary treatment. Especially in recurrent disease, exact localization of the diseased tissue or nodes may help to reduce the extent of the operative procedure. In this chapter the role of radioguided surgery for completion thyroidectomy in patients with differentiated and medullary thyroid cancer, and for reoperation in cases of recurrence, will be discussed; both iodine-guided and non-iodine-guided procedures will be considered.

Radioguided surgery is a very useful tool to administer minimal-invasive surgery in thyroid cancer.

Keywords

Thyroid cancer Recurrence Radioguided surgery Iodine Completion thyroidectomy 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.Google Scholar
  2. 2.
    Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol. 2013;2013:965212.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–403.CrossRefPubMedGoogle Scholar
  4. 4.
    Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–214.CrossRefPubMedGoogle Scholar
  5. 5.
    Davies L, Welch HG. Thyroid cancer survival in the United States: observational data from 1973 to 2005. Arch Otolaryngol Head Neck Surg. 2010;136(5):440–4.CrossRefPubMedGoogle Scholar
  6. 6.
    Yu XM, Schneider DF, Leverson G, Chen H, Sippel RS. Follicular variant of papillary thyroid carcinoma is a unique clinical entity: a population-based study of 10,740 cases. Thyroid. 2013;23(10):1263–8.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Mazzaferri EL. An overview of the management of papillary and follicular thyroid carcinoma. Thyroid. 1999;9(5):421–7.CrossRefPubMedGoogle Scholar
  8. 8.
    Rouxel A, Hejblum G, Bernier MO, Boelle PY, Menegaux F, Mansour G, et al. Prognostic factors associated with the survival of patients developing loco-regional recurrences of differentiated thyroid carcinomas. J Clin Endocrinol Metab. 2004;89(11):5362–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Leboulleux S, Rubino C, Baudin E, Caillou B, Hartl DM, Bidart JM, et al. Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. J Clin Endocrinol Metab. 2005;90(10):5723–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86(4):1447–63.CrossRefPubMedGoogle Scholar
  11. 11.
    Mirallie E, Hamy A, Floch I, Sagan C, Paineau J, Murat A, et al. Outcome in cervical recurrences of papillary or follicular thyroid cancer. Ann Chir. 1999;53(7):577–82. Devenir des recidives cervicales de cancer papillaire ou vesiculaire de la thyroide.PubMedGoogle Scholar
  12. 12.
    Goffredo P, Roman SA, Sosa JA. Hurthle cell carcinoma: a population-level analysis of 3311 patients. Cancer. 2013;119(3):504–11.CrossRefPubMedGoogle Scholar
  13. 13.
    de Groot JW, Plukker JT, Wolffenbuttel BH, Wiggers T, Sluiter WJ, Links TP. Determinants of life expectancy in medullary thyroid cancer: age does not matter. Clin Endocrinol (Oxf). 2006;65(6):729–36.CrossRefGoogle Scholar
  14. 14.
    Bergamaschi R, Becouarn G, Ronceray J, Arnaud JP. Morbidity of thyroid surgery. Am J Surg. 1998;176(1):71–5.CrossRefPubMedGoogle Scholar
  15. 15.
    Shah MD, Harris LD, Nassif RG, Kim D, Eski S, Freeman JL. Efficacy and safety of central compartment neck dissection for recurrent thyroid carcinoma. Arch Otolaryngol Head Neck Surg. 2012;138(1):33–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Carcoforo P, Portinari M, Feggi L, Panareo S, De Troia A, Zatelli MC, et al. Radio-guided selective compartment neck dissection improves staging in papillary thyroid carcinoma: a prospective study on 345 patients with a 3-year follow-up. Surgery. 2014;156(1):147–57.CrossRefPubMedGoogle Scholar
  17. 17.
    Dhepnorrarat RC, Witterick IJ. New technologies in thyroid cancer surgery. Oral Oncol. 2013;49(7):659–64.CrossRefPubMedGoogle Scholar
  18. 18.
    Aras G, Gultekin SS, Kucuk NO, Demirer S, Tug T. Intraoperative gamma probe guidance with 99mTc-pertechnetate in the completion thyroidectomy. Ann Nucl Med. 2009;23(5):421–6.CrossRefPubMedGoogle Scholar
  19. 19.
    Erbil Y, Barbaros U, Deveci U, Kaya H, Bozbora A, Ozbey N, et al. Gamma probe-guided surgery for revision thyroidectomy: in comparison with conventional technique. J Endocrinol Invest. 2005;28(7):583–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Karyagar S, Karatepe O, Bender O, Mulazimoglu M, Ozpacaci T, Uyanik E, et al. Tc-99m radio-guided completion thyroidectomy for differentiated thyroid carcinoma. Indian J Nucl Med. 2010;25(1):12–5.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Proczko M, Stefaniak T, Sworczak K, Kobiela J, Lachinski AJ, Stepaniak P, et al. Completion thyroidectomy of well-differentiated thyroid cancer – a prospective, randomised study. Endokrynol Pol. 2013;64(5):335–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Uludag M, Yetkin G, Citgez B, Isgor A, Atay M, Kebudi A, et al. Contribution of gamma probe-guided surgery to lateral approach completion thyroidectomy. Endocr Pract. 2009;15(3):213–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Pacini F, Elisei R, Capezzone M, Miccoli P, Molinaro E, Basolo F, et al. Contralateral papillary thyroid cancer is frequent at completion thyroidectomy with no difference in low- and high-risk patients. Thyroid. 2001;11(9):877–81.CrossRefPubMedGoogle Scholar
  24. 24.
    Pasieka JL, Thompson NW, McLeod MK, Burney RE, Macha M. The incidence of bilateral well-differentiated thyroid cancer found at completion thyroidectomy. World J Surg. 1992;16(4):711–6. discussion 6–7.CrossRefPubMedGoogle Scholar
  25. 25.
    Kim ES, Kim TY, Koh JM, Kim YI, Hong SJ, Kim WB, et al. Completion thyroidectomy in patients with thyroid cancer who initially underwent unilateral operation. Clin Endocrinol (Oxf). 2004;61(1):145–8.CrossRefGoogle Scholar
  26. 26.
    Hayward NJ, Grodski S, Yeung M, Johnson WR, Serpell J. Recurrent laryngeal nerve injury in thyroid surgery: a review. ANZ J Surg. 2013;83(1–2):15–21.CrossRefPubMedGoogle Scholar
  27. 27.
    Bender O, Karyagar S, Levent Balci F, Yuney E, Kamali S, Ozpacaci T, et al. Gamma probe (99m)Tc-pertechnetate assisted completion thyroidectomy vs conventional thyroidectomy in differentiated thyroid carcinoma. Hell J Nucl Med. 2009;12(2):138–41.PubMedGoogle Scholar
  28. 28.
    Harris C, Bigelow R, Francis J, Kelly G, Bell P. A Cis(Ti)-crystal surgical scintillation probe. Nucleonics. 1956;14:102–8.Google Scholar
  29. 29.
    Morris Jr AC, Barclay TR, Tanida R, Nemcek JV. A miniaturized probe for detecting radioactivity at thyroid surgery. Phys Med Biol. 1971;16(3):397–404.CrossRefPubMedGoogle Scholar
  30. 30.
    Travagli JP, Cailleux AF, Ricard M, Baudin E, Caillou B, Parmentier C, et al. Combination of radioiodine (131I) and probe-guided surgery for persistent or recurrent thyroid carcinoma. J Clin Endocrinol Metab. 1998;83(8):2675–80.CrossRefPubMedGoogle Scholar
  31. 31.
    Lippi F, Capezzone M, Miccoli P, Traino C, Di Martino F, Angelini F, et al. Use of surgical gamma probe for the detection of lymph node metastases in differentiated thyroid cancer. Tumori. 2000;86(4):367–9.PubMedGoogle Scholar
  32. 32.
    Salvatori M, Rufini V, Reale F, Samanes Gajate AM, Maussier ML, Revelli L, et al. Radio-guided surgery for lymph node recurrences of differentiated thyroid cancer. World J Surg. 2003;27(7):770–5.CrossRefPubMedGoogle Scholar
  33. 33.
    Rubello D, Salvatori M, Ardito G, Mariani G, Al-Nahhas A, Gross MD, et al. Iodine-131 radio-guided surgery in differentiated thyroid cancer: outcome on 31 patients and review of the literature. Biomed Pharmacother. 2007;61(8):477–81.CrossRefPubMedGoogle Scholar
  34. 34.
    Scurry WC, Lamarre E, Stack B. Radioguided neck dissection in recurrent metastatic papillary thyroid carcinoma. Am J Otolaryngol. 2006;27(1):61–3.CrossRefPubMedGoogle Scholar
  35. 35.
    Negele T, Meisetschlager G, Bruckner T, Scheidhauer K, Schwaiger M, Vogelsang H. Radio-guided surgery for persistent differentiated papillary thyroid cancer: case presentations and review of the literature. Langenbecks Arch Surg. 2006;391(3):178–86.CrossRefPubMedGoogle Scholar
  36. 36.
    Littmann K, Magdsick G, Strotges MW, Eigler FW. Intraoperative localization measurement following preoperative radioiodine marking to facilitate the treatment of differentiated thyroid carcinoma. Chirurg. 1980;51(6):389–94. Intraoperative Lokalisationsmessung nach praoperativer Radiojodmarkierung zur Verbesserung der Behandlung differenzierter Schilddrusencarcinome.PubMedGoogle Scholar
  37. 37.
    Gallowitsch HJ, Fellinger J, Mikosch P, Kresnik E, Lind P. Gamma probe-guided resection of a lymph node metastasis with I-123 in papillary thyroid carcinoma. Clin Nucl Med. 1997;22(9):591–2.CrossRefPubMedGoogle Scholar
  38. 38.
    Mansberg R, Crawford B, Uren RF, Thompson JF. Minimally invasive radio-guided surgery for recurrent thyroid cancer using iodine-123. Clin Nucl Med. 2005;30(1):43–4.CrossRefPubMedGoogle Scholar
  39. 39.
    Khandelwal S, Sener SF, Purdy L, Perlman RM. I-123-guided excision of metastatic papillary thyroid cancer. J Surg Oncol. 2007;96(2):173–5.CrossRefPubMedGoogle Scholar
  40. 40.
    Gulec SA, Eckert M, Woltering EA. Gamma probe-guided lymph node dissection (‘gamma picking’) in differentiated thyroid carcinoma. Clin Nucl Med. 2002;27(12):859–61.CrossRefPubMedGoogle Scholar
  41. 41.
    Helal BO, Merlet P, Toubert ME, Franc B, Schvartz C, Gauthier-Koelesnikov H, et al. Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy. J Nucl Med. 2001;42(10):1464–9.PubMedGoogle Scholar
  42. 42.
    Frilling A, Tecklenborg K, Gorges R, Weber F, Clausen M, Broelsch EC. Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma. Ann Surg. 2001;234(6):804–11.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Pacini F, Agate L, Elisei R, Capezzone M, Ceccarelli C, Lippi F, et al. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. J Clin Endocrinol Metab. 2001;86(9):4092–7.CrossRefPubMedGoogle Scholar
  44. 44.
    Rubello D, Mazzarotto R, Casara D. The role of technetium-99m methoxyisobutylisonitrile scintigraphy in the planning of therapy and follow-up of patients with differentiated thyroid carcinoma after surgery. Eur J Nucl Med. 2000;27(4):431–40.CrossRefPubMedGoogle Scholar
  45. 45.
    Elser H, Henze M, Hermann C, Eckert W, Mende U. 99m-Tc-MIBI for recurrent and metastatic differentiated thyroid carcinoma. Nuklearmedizin. 1997;36(1):7–12. 99mTc-MIBI zur Rezidiv- und Metastasensuche bei differenzierten Schilddrusenkarzinomen.PubMedGoogle Scholar
  46. 46.
    Rubello D, Saladini G, Carpi A, Casara D. Nuclear medicine imaging procedures in differentiated thyroid carcinoma patients with negative iodine scan. Biomed Pharmacother. 2000;54(6):337–44.CrossRefPubMedGoogle Scholar
  47. 47.
    Wu HS, Liu FY, Huang WS, Liu YC, Chang CT, Kao CH. Technetium-99m tetrofosmin single photon emission computed tomography to detect metastatic papillary thyroid carcinoma in patients with elevated human serum thyroglobulin levels but negative I-131 whole body scan. Clin Radiol. 2003;58(10):787–90.CrossRefPubMedGoogle Scholar
  48. 48.
    Fujie S, Okumura Y, Sato S, Akaki S, Katsui K, Himei K, et al. Diagnostic capabilities of I-131, TI-201, and Tc-99m-MIBI scintigraphy for metastatic differentiated thyroid carcinoma after total thyroidectomy. Acta Med Okayama. 2005;59(3):99–107.PubMedGoogle Scholar
  49. 49.
    Kucuk NO, Kulak HA, Aras G. Clinical importance of technetium-99m-methoxyisobutylisonitrile (MIBI) scintigraphy in differentiated thyroid carcinoma patients with elevated thyroglobulin levels and negative I-131 scanning results. Ann Nucl Med. 2006;20(6):393–7.CrossRefPubMedGoogle Scholar
  50. 50.
    Iwata M, Kasagi K, Misaki T, Matsumoto K, Iida Y, Ishimori T, et al. Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPET, and post-therapeutic 131I-Na scintigraphy in the detection of metastatic thyroid cancer. Eur J Nucl Med Mol Imaging. 2004;31(4):491–8.CrossRefPubMedGoogle Scholar
  51. 51.
    Alam MS, Kasagi K, Misaki T, Miyamoto S, Iwata M, Iida Y, et al. Diagnostic value of technetium-99m methoxyisobutyl isonitrile (99mTc-MIBI) scintigraphy in detecting thyroid cancer metastases: a critical evaluation. Thyroid. 1998;8(12):1091–100.CrossRefPubMedGoogle Scholar
  52. 52.
    Hsu CH, Liu FY, Yen RF, Kao CH. Tc-99m MIBI SPECT in detecting metastatic papillary thyroid carcinoma in patients with elevated human serum thyroglobulin levels but negative I-131 whole body scan. Endocr Res. 2003;29(1):9–15.CrossRefPubMedGoogle Scholar
  53. 53.
    Boz A, Arici C, Gungor F, Yildiz A, Colak T, Karayalcin B. Gamma probe-guided resection and scanning with TC-99m MIBI of a local recurrence of follicular thyroid carcinoma. Clin Nucl Med. 2001;26(10):820–2.CrossRefPubMedGoogle Scholar
  54. 54.
    Rubello D, Piotto A, Pagetta C, Pelizzo MR, Casara D. (99m)Tc-MIBI radio-guided surgery for recurrent thyroid carcinoma: technical feasibility and procedure, and preliminary clinical results. Eur J Nucl Med Mol Imaging. 2002;29(9):1201–5.CrossRefPubMedGoogle Scholar
  55. 55.
    Rubello D, Pelizzo MR, Casara D, Piotto A, Toniato A, Fig L, et al. Radio-guided surgery for non-131I-avid thyroid cancer. Thyroid. 2006;16(11):1105–11.CrossRefPubMedGoogle Scholar
  56. 56.
    Rubello D, Salvatori M, Casara D, Piotto A, Toniato A, Gross MD, et al. 99mTc-sestamibi radio-guided surgery of loco-regional 131Iodine-negative recurrent thyroid cancer. Eur J Surg Oncol. 2007;33(7):902–6.CrossRefPubMedGoogle Scholar
  57. 57.
    Dong MJ, Liu ZF, Zhao K, Ruan LX, Wang GL, Yang SY, et al. Value of 18F-FDG-PET/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan: a meta-analysis. Nucl Med Commun. 2009;30(8):639–50.CrossRefPubMedGoogle Scholar
  58. 58.
    Weber T, Ohlhauser D, Hillenbrand A, Henne-Bruns D, Reske SN, Luster M. Impact of FDG-PET computed tomography for surgery of recurrent or persistent differentiated thyroid carcinoma. Horm Metab Res. 2012;44(12):904–8.CrossRefPubMedGoogle Scholar
  59. 59.
    Seo JH, Lee SW, Ahn BC, Lee J. Recurrence detection in differentiated thyroid cancer patients with elevated serum level of antithyroglobulin antibody: special emphasis on using (18)F-FDG PET/CT. Clin Endocrinol (Oxf). 2010;72(4):558–63.CrossRefGoogle Scholar
  60. 60.
    Essner R, Hsueh EC, Haigh PI, Glass EC, Huynh Y, Daghighian F. Application of an [(18)F]fluorodeoxyglucose-sensitive probe for the intraoperative detection of malignancy. J Surg Res. 2001;96(1):120–6.CrossRefPubMedGoogle Scholar
  61. 61.
    Zervos EE, Desai DC, DePalatis LR, Soble D, Martin EW. 18F-labeled fluorodeoxyglucose positron emission tomography-guided surgery for recurrent colorectal cancer: a feasibility study. J Surg Res. 2001;97(1):9–13.CrossRefPubMedGoogle Scholar
  62. 62.
    Kraeber-Bodere F, Cariou B, Curtet C, Bridji B, Rousseau C, Dravet F, et al. Feasibility and benefit of fluorine 18-fluoro-2-deoxyglucose-guided surgery in the management of radioiodine-negative differentiated thyroid carcinoma metastases. Surgery. 2005;138(6):1176–82. discussion 82.CrossRefPubMedGoogle Scholar
  63. 63.
    Meller B, Sahlmann C, Horstmann O, Gerl J, Baehre M, Meller J. Conventional gamma and high energy probe for radioguided dissection of metastases in a patient with recurrent thyroid carcinoma with (99m)Tc-MIBI and (18)F-FDG. Nuklearmedizin. 2005;44(3):N23–5.PubMedGoogle Scholar
  64. 64.
    Curtet C, Carlier T, Mirallie E, Bodet-Milin C, Rousseau C, Barbet J, et al. Prospective comparison of two gamma probes for intraoperative detection of 18F-FDG: in vitro assessment and clinical evaluation in differentiated thyroid cancer patients with iodine-negative recurrence. Eur J Nucl Med Mol Imaging. 2007;34(10):1556–62.CrossRefPubMedGoogle Scholar
  65. 65.
    Gulec SA, Hoenie E, Hostetter R, Schwartzentruber D. PET probe-guided surgery: applications and clinical protocol. World J Surg Oncol. 2007;5:65.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Agrawal A, Hall NC, Ringel MD, Povoski SP, Martin Jr EW. Combined use of perioperative TSH-stimulated (18)F-FDG PET/CT imaging and gamma probe radioguided surgery to localize and verify resection of iodine scan-negative recurrent thyroid carcinoma. Laryngoscope. 2008;118(12):2190–4.CrossRefPubMedGoogle Scholar
  67. 67.
    Francis CL, Nalley C, Fan C, Bodenner D, Stack Jr BC. 18F-fluorodeoxyglucose and 131I radioguided surgical management of thyroid cancer. Otolaryngol Head Neck Surg. 2012;146(1):26–32.CrossRefPubMedGoogle Scholar
  68. 68.
    Nalley C, Wiebeck K, Bartel TB, Bodenner D, Stack Jr BC. Intraoperative radiation exposure with the use of (18)F-FDG-guided thyroid cancer surgery. Otolaryngol Head Neck Surg. 2010;142(2):281–3.CrossRefPubMedGoogle Scholar
  69. 69.
    Tukenmez M, Erbil Y, Barbaros U, Dural C, Salmaslioglu A, Aksoy D, et al. Radio-guided nonpalpable metastatic lymph node localization in patients with recurrent thyroid cancer. J Surg Oncol. 2007;96(6):534–8.CrossRefPubMedGoogle Scholar
  70. 70.
    Erbil Y, Sari S, Agcaoglu O, Ersoz F, Bayraktar A, Salmaslioglu A, et al. Radio-guided excision of metastatic lymph nodes in thyroid carcinoma: a safe technique for previously operated neck compartments. World J Surg. 2010;34(11):2581–8.CrossRefPubMedGoogle Scholar
  71. 71.
    Terzioglu T, Senyurek YG, Tunca F, Turkmen C, Mudun A, Salmaslioglu A, et al. Excision efficiency of radioguided occult lesion localization in reoperative thyroid and parathyroid surgery. Thyroid. 2010;20(11):1271–8.CrossRefPubMedGoogle Scholar
  72. 72.
    Martino A, Monaco L, Golia R, Miletto P, Capasso P, Lombardi C, et al. A new radioguided procedure for localization and surgical treatment of neck node metastasis of papillary thyroid cancer. J Endocrinol Invest. 2010;33(5):339–42.CrossRefPubMedGoogle Scholar
  73. 73.
    Ilgan S, Ozturk E, Yildiz R, Emer O, Ayan A, Gorgulu S, et al. Combination of preoperative ultrasonographic mapping and radioguided occult lesion localization in patients with locally recurrent/persistent papillary thyroid carcinoma: a practical method for central compartment reoperations. Clin Nucl Med. 2010;35(11):847–52.CrossRefPubMedGoogle Scholar
  74. 74.
    Borso E, Grosso M, Boni G, Manca G, Bianchi P, Puccini M, et al. Radioguided occult lesion localization of cervical recurrences from differentiated thyroid cancer: technical feasibility and clinical results. Q J Nucl Med Mol Imaging. 2013;57(4):401–11.PubMedGoogle Scholar
  75. 75.
    Giles YS, Sarici IS, Tunca F, Sormaz IC, Salmaslioglu A, Adalet I, et al. The rate of operative success achieved with radioguided occult lesion localization and intraoperative ultrasonography in patients with recurrent papillary thyroid cancer. Surgery. 2014;156:1116–26.CrossRefPubMedGoogle Scholar
  76. 76.
    Jung YS, Kim SK, Park I, Ryu J, Kim SW, Lee CY, et al. Surgical targeting of recurrent thyroid cancer using a novel mixture of 99m-technetium macroaggregated albumin and indocyanine green. Surg Innov. 2014;21:622–9.CrossRefPubMedGoogle Scholar
  77. 77.
    Giovanella L, Suriano S, Lunghi L, Bongiovanni M, Ceriani L. Radioguided surgery of thyroid carcinoma recurrences: the role of preoperative (99m)Tc-labeled human serum albumin macroaggregates-SPECT/CT mapping. Clin Nucl Med. 2013;38(4):e207–9.CrossRefPubMedGoogle Scholar
  78. 78.
    Bellotti C, Castagnola G, Tierno SM, Centanini F, Sparagna A, Vetrone I, et al. Radioguided surgery with combined use of gamma probe and hand-held gamma camera for treatment of papillary thyroid cancer locoregional recurrences: a preliminary study. Eur Rev Med Pharmacol Sci. 2013;17(24):3362–6.PubMedGoogle Scholar
  79. 79.
    Alander JT, Kaartinen I, Laakso A, Patila T, Spillmann T, Tuchin VV, et al. A review of indocyanine green fluorescent imaging in surgery. Int J Biomed Imaging. 2012;2012:940585.CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009;19(6):565–612.CrossRefPubMedGoogle Scholar
  81. 81.
    Leboulleux S, Baudin E, Travagli JP, Schlumberger M. Medullary thyroid carcinoma. Clin Endocrinol (Oxf). 2004;61(3):299–310.CrossRefGoogle Scholar
  82. 82.
    Skoura E. Depicting medullary thyroid cancer recurrence: the past and the future of nuclear medicine imaging. Int J Endocrinol Metab. 2013;11(4), e8156.CrossRefPubMedPubMedCentralGoogle Scholar
  83. 83.
    Ugur O, Kostakglu L, Guler N, Caner B, Uysal U, Elahi N, et al. Comparison of 99mTc(V)-DMSA, 201Tl and 99mTc-MIBI imaging in the follow-up of patients with medullary carcinoma of the thyroid. Eur J Nucl Med. 1996;23(10):1367–71.CrossRefPubMedGoogle Scholar
  84. 84.
    Reiners C. Imaging methods for medullary thyroid cancer. Recent Results Cancer Res. 1992;125:125–45.CrossRefPubMedGoogle Scholar
  85. 85.
    Arslan N, Ilgan S, Yuksel D, Serdengecti M, Bulakbasi N, Ugur O, et al. Comparison of In-111 octreotide and Tc-99m (V) DMSA scintigraphy in the detection of medullary thyroid tumor foci in patients with elevated levels of tumor markers after surgery. Clin Nucl Med. 2001;26(8):683–8.CrossRefPubMedGoogle Scholar
  86. 86.
    Adams S, Baum RP, Hertel A, Wenisch HJ, Staib-Sebler E, Herrmann G, et al. Intraoperative gamma probe detection of neuroendocrine tumors. J Nucl Med. 1998;39(7):1155–60.PubMedGoogle Scholar
  87. 87.
    Adams S, Acker P, Lorenz M, Staib-Sebler E, Hor G. Radioisotope-guided surgery in patients with pheochromocytoma and recurrent medullary thyroid carcinoma: a comparison of preoperative and intraoperative tumor localization with histopathologic findings. Cancer. 2001;92(2):263–70.CrossRefPubMedGoogle Scholar
  88. 88.
    Adams S, Baum RP. Intraoperative use of gamma-detecting probes to localize neuroendocrine tumors. Q J Nucl Med. 2000;44(1):59–67.PubMedGoogle Scholar
  89. 89.
    Sandrock D, Blossey HC, Steinroeder M, Munz DL. Contribution of different scintigraphic techniques to the management of medullary thyroid carcinoma. Henry Ford Hosp Med J. 1989;37(3–4):173–4.PubMedGoogle Scholar
  90. 90.
    Behr TM, Gratz S, Markus PM, Dunn RM, Hufner M, Schauer A, et al. Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors? Cancer. 1997;80(12 Suppl):2436–57.CrossRefPubMedGoogle Scholar
  91. 91.
    Busnardo B, Girelli ME, Simioni N, Nacamulli D, Busetto E. Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinoma. Cancer. 1984;53(2):278–85.CrossRefPubMedGoogle Scholar
  92. 92.
    Barbet J, Peltier P, Bardet S, Vuillez JP, Bachelot I, Denet S, et al. Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody. J Nucl Med. 1998;39(7):1172–8.PubMedGoogle Scholar
  93. 93.
    de Labriolle-Vaylet C, Cattan P, Sarfati E, Wioland M, Billotey C, Brocheriou C, et al. Successful surgical removal of occult metastases of medullary thyroid carcinoma recurrences with the help of immunoscintigraphy and radioimmunoguided surgery. Clin Cancer Res. 2000;6(2):363–71.PubMedGoogle Scholar
  94. 94.
    Peltier P, Curtet C, Chatal JF, Le Doussal JM, Daniel G, Aillet G, et al. Radioimmunodetection of medullary thyroid cancer using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer. J Nucl Med. 1993;34(8):1267–73.PubMedGoogle Scholar
  95. 95.
    Wangberg B, Forssell-Aronsson E, Tisell LE, Nilsson O, Fjalling M, Ahlman H. Intraoperative detection of somatostatin-receptor-positive neuroendocrine tumours using indium-111-labelled DTPA-D-Phe1-octreotide. Br J Cancer. 1996;73(6):770–5.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Christina Bluemel
    • 1
  • Ken Herrmann
    • 1
  • Gerhard Wolf
    • 2
  • Giorgo Castagnola
    • 3
  • Carlo Bellotti
    • 3
  1. 1.Department of Nuclear MedicineUniversity Hospital of WürzburgWürzburgGermany
  2. 2.Endocrine SurgeryUniversity of GrazGrazAustria
  3. 3.Operative Unit Surgery of Thyroid and ParathyroidSapienza University of Rome, S. Andrea HospitalRomeItaly

Personalised recommendations